1. Kite and Refuge Biotechnologies announce exclusive licence agreement for investigational gene expression platform for blood cancers
- Subjects
Gene expression -- Genetic aspects ,Genes -- Genetic aspects ,Biotechnology -- Genetic aspects ,Biotechnology industry -- Licensing agreements ,Cancer -- Genetic aspects -- Care and treatment ,Multiple myeloma -- Genetic aspects -- Care and treatment ,Company licensing agreement ,Business ,Chemicals, plastics and rubber industries - Abstract
Kite, a Gilead Company, and Refuge Biotechnologies Inc announced on 20 Oct 2022 that Kite has entered into an exclusive, worldwide licence agreement with Refuge, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize Refuge's proprietary gene expression platform to develop potential treatments for blood cancers. Refuge's proprietary platform is a synthetic biology system that utilizes an expression modulation strategy to repress or activate transcription of target genes. Early preclinical data suggest a potential for this highly modular platform to regulate target antigen-dependent gene expression as a means to improve upon both the efficacy and safety of first-generation CAR T-cell therapies. Kite will have an exclusive license to Refuge's intellectual property portfolio for use in blood cancers, as well as a library of synthetic gene expression programmes for these indications. Refuge will retain all rights and programmes related to solid tumour indications. Under the terms of the agreement, Kite will be responsible for all costs and activities related to research, development, manufacturing and commercialization. Kite will also make an upfront payment to Refuge and Refuge will be eligible to receive potential performance-based regulatory milestone payments. Original source: Gilead, website: http://www.gilead.com/, Copyright Gilead 2022., patents and technical know-how; research and development; anticancer drugs; cell therapies; immunotherapeutics; Gilead; Kite; Refuge [...]
- Published
- 2022